Manning & Napier Advisors LLC Raises Stock Position in GSK plc (NYSE:GSK)

Manning & Napier Advisors LLC grew its holdings in shares of GSK plc (NYSE:GSK) by 33.3% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 200,000 shares of the pharmaceutical company’s stock after buying an additional 50,000 shares during the quarter. Manning & Napier Advisors LLC’s holdings in GSK were worth $6,764,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in the business. Eastern Bank bought a new stake in GSK during the third quarter worth approximately $26,000. ST Germain D J Co. Inc. increased its position in shares of GSK by 195.5% during the 4th quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock valued at $27,000 after purchasing an additional 522 shares during the last quarter. Sunbelt Securities Inc. raised its holdings in GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock valued at $29,000 after buying an additional 302 shares during the period. Concord Wealth Partners lifted its position in GSK by 231.8% in the third quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock worth $32,000 after buying an additional 547 shares during the last quarter. Finally, Fortitude Family Office LLC purchased a new position in GSK during the third quarter worth $42,000. Institutional investors own 15.74% of the company’s stock.

GSK Stock Performance

GSK stock opened at $35.06 on Thursday. The company has a debt-to-equity ratio of 0.98, a quick ratio of 0.53 and a current ratio of 0.81. The company has a market capitalization of $72.67 billion, a PE ratio of 22.77, a P/E/G ratio of 1.31 and a beta of 0.63. The company has a 50 day moving average price of $33.98 and a 200-day moving average price of $37.75. GSK plc has a fifty-two week low of $31.72 and a fifty-two week high of $45.92.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on GSK shares. Deutsche Bank Aktiengesellschaft lowered shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and dropped their target price for the company from $53.00 to $39.50 in a research report on Tuesday, November 12th. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a report on Thursday, October 31st. Finally, StockNews.com cut GSK from a “strong-buy” rating to a “buy” rating in a report on Tuesday, January 21st. Six analysts have rated the stock with a hold rating, one has assigned a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $43.25.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.